Home/Pipeline/AmorphOX Vaccine

AmorphOX Vaccine

Infectious Disease

PreclinicalActive (with Abera)

Key Facts

Indication

Infectious Disease

Phase

Preclinical

Status

Active (with Abera)

Company

Orexo

About Orexo

Orexo is a publicly traded Swedish pharmaceutical company that has evolved from an R&D-focused entity into a commercial organization with a hybrid business model. Its strategic foundation is the proprietary AmorphOX® powder-based drug delivery technology, designed to improve bioavailability and stability for critical medicines. Following the transformative 2025 divestment of its flagship product Zubsolv® in the US, the company is executing a three-pillar growth strategy focused on becoming a global leader in nasal powder delivery, advancing a diversified pipeline to key value inflection points, and establishing technology partnerships.

View full company profile

Therapeutic Areas

Addiction Medicine Allergy/Immunology Metabolic Disorders Infectious Disease

Other Infectious Disease Drugs

Drug	Company	Phase	Status
Vaccine Platform	Biolingus	Research	Active
Pipeline Antibiotics	BioQ Pharma	Unknown	Active
Antivirals Platform	Qubit Pharmaceuticals	Discovery	Active
Antibiotic Development Program	AF ChemPharm	Pre-clinical	Active
Prophylactic Vaccine Development	ImmuneSpec	Service	Active
Optimized VHH vs. SARS-CoV-2	Ordaos Bio	Pre-clinical	Active
Undisclosed Vaccine Program(s)	Brazos Biomedical	Pre-clinical	Active
Undisclosed Asset 1	Uvax Bio	Research	Active
Undisclosed Asset 2	Uvax Bio	Research	Active
Undisclosed Asset 3	Uvax Bio	Research	Active
Vaccine Immune Response (SARS-CoV-2)	CellChorus	Preclinical	Active
XmAb®662	Xencor	Preclinical	Active